DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Tewari KS. et al.
Bevacizumab for advanced cervical cancer: final overall survival and adverse
event analysis of a randomised, controlled, open-label, phase 3 trial
(Gynecologic Oncology Group 240).
The Lancet 2017;
390 (10103) 1654-1663
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.